Functional overlap between chondroitin and heparan sulfate proteoglycans during VEGF-induced sprouting angiogenesis

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 32, Issue 5, 2012, Pages 1255-1263

  Jan, Sébastien Le ^b   Hayashi, Makoto ^a   Kasza, Zsolt ^b   Eriksson, Inger ^b   Bishop, Joseph R ^c   Weibrecht, Irene ^a   Heldin, Johan ^b   Holmborn, Katarina ^b   Jakobsson, Lars ^d   Söderberg, Ola ^a   Spillmann, Dorothe ^b   Esko, Jeffrey D ^c   Claesson Welsh, Lena ^a   Kjellén, Lena ^b   Kreuger, Johan ^b  

^a Genetics and Pathology ^*  (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Angiogenesis; Biology, developmental; Endothelium; Glycosominoglycan; Vascular biology

Indexed keywords

DECORIN; MEMBRANE PROTEIN; MEMBRANE PROTEIN NG2; MESSENGER RNA; PLATELET DERIVED GROWTH FACTOR B; PROTEOCHONDROITIN SULFATE; PROTEOHEPARAN SULFATE; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; VASCULOTROPIN A;

ANGIOGENESIS; ANIMAL CELL; ARTICLE; CELL ADHESION; CELL COUNT; CELL DIFFERENTIATION; CONTROLLED STUDY; EMBRYONIC STEM CELL; GLYCOPROTEIN SYNTHESIS; MOUSE; NONHUMAN; PERICYTE; PRIORITY JOURNAL; PROTEIN INTERACTION; SIGNAL TRANSDUCTION;

ANIMALS; BLOTTING, WESTERN; CELL ADHESION; CELL PROLIFERATION; CELLS, CULTURED; CHONDROITIN; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; HEPARAN SULFATE PROTEOGLYCANS; IMMUNOHISTOCHEMISTRY; MICE; NEOVASCULARIZATION, PATHOLOGIC; PROTEOGLYCANS; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84860222957     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.111.240622     Document Type: Article

References (47)

1. Carmeliet P. Angiogenesis in life, disease and medicine. Nature. 2005;438:932-936. (Pubitemid 43093958)
2. Adams RH, Alitalo K. Molecular regulation of angiogenesis and lymphangiogenesis. Nat Rev Mol Cell Biol. 2007;8:464-478. (Pubitemid 46823443)
3. Iozzo RV, Zoeller JJ, Nystrom A. Basement membrane proteoglycans: modulators Par Excellence of cancer growth and angiogenesis. Mol Cells. 2009;27:503-513.
4. Yayon A, Klagsbrun M, Esko JD, Leder P, Ornitz DM. Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor. Cell. 1991;64:841-848. (Pubitemid 121001170)
5. Pellegrini L, Burke DF, von Delft F, Mulloy B, Blundell TL. Crystal structure of fibroblast growth factor receptor ectodomain bound to ligand and heparin. Nature. 2000;407:1029-1034.
6. Rolny C, Spillmann D, Lindahl U, Claesson-Welsh L. Heparin amplifies platelet-derived growth factor (PDGF)-BB-induced PDGF alpha-receptor but not PDGF beta-receptor tyrosine phosphorylation in heparan sulfate-deficient cells. Effects on signal transduction and biological responses. J Biol Chem. 2002;277:19315-19321. (Pubitemid 34967436)
7. Ashikari-Hada S, Habuchi H, Kariya Y, Kimata K. Heparin regulates vascular endothelial growth factor165-dependent mitogenic activity, tube formation, and its receptor phosphorylation of human endothelial cells. Comparison of the effects of heparin and modified heparins. J Biol Chem. 2005;280:31508-31515. (Pubitemid 41291893)
8. Mohammadi M, Olsen SK, Ibrahimi OA. Structural basis for fibroblast growth factor receptor activation. Cytokine Growth Factor Rev. 2005;16:107-137. (Pubitemid 40616111)
9. Jakobsson L, Kreuger J, Holmborn K, Lundin L, Eriksson I, Kjellen L, Claesson-Welsh L. Heparan sulfate in trans potentiates VEGFR-mediated angiogenesis. Dev Cell. 2006;10:625-634.
10. Abramsson A, Kurup S, Busse M, Yamada S, Lindblom P, Schallmeiner E, Stenzel D, Sauvaget D, Ledin J, Ringvall M, Landegren U, Kjellen L, Bondjers G, Li JP, Lindahl U, Spillmann D, Betsholtz C, Gerhardt H. Defective N-sulfation of heparan sulfate proteoglycans limits PDGF-BB binding and pericyte recruitment in vascular development. Genes Dev. 2007;21:316-331.
11. Rudd TR, Skidmore MA, Guerrini M, Hricovini M, Powell AK, Siligardi G, Yates EA. The conformation and structure of GAGs: recent progress and perspectives. Curr Opin Struct Biol. 2010;20:567-574.
12. Kreuger J, Spillmann D, Li JP, Lindahl U. Interactions between heparan sulfate and proteins: the concept of specificity. J Cell Biol. 2006;174:323-327. (Pubitemid 44156762)
13. Lindblom P, Gerhardt H, Liebner S, Abramsson A, Enge M, Hellstrom M, Backstrom G, Fredriksson S, Landegren U, Nystrom HC, Bergstrom G, Dejana E, Ostman A, Lindahl P, Betsholtz C. Endothelial PDGF-B retention is required for proper investment of pericytes in the microvessel wall. Genes Dev. 2003;17:1835-1840. (Pubitemid 36944561)
14. Fuster MM, Wang L, Castagnola J, Sikora L, Reddi K, Lee PH, Radek KA, Schuksz M, Bishop JR, Gallo RL, Sriramarao P, Esko JD. Genetic alteration of endothelial heparan sulfate selectively inhibits tumor angiogenesis. J Cell Biol. 2007;177:539-549. (Pubitemid 46718281)
15. Stenzel D, Nye E, Nisancioglu M, Adams RH, Yamaguchi Y, Gerhardt H. Peripheral mural cell recruitment requires cell-autonomous heparan sulfate. Blood. 2009;114:915-924.
16. Lin X, Wei G, Shi Z, Dryer L, Esko JD, Wells DE, Matzuk MM. Disruption of gastrulation and heparan sulfate biosynthesis in EXT1-deficient mice. Dev Biol. 2000;224:299-311. (Pubitemid 30661012)
17. Ringvall M, Kjellen L. Mice deficient in heparan sulfate N-deacetylase/N-sulfotransferase 1. Prog Mol Biol Transl Sci. 2010;93:35-58.
18. Nagy A, Rossant J, Nagy R, Abramow-Newerly W, Roder JC. Derivation of completely cell culture-derived mice from early-passage embryonic stem cells. Proc Natl Acad Sci USA. 1993;90:8424-8428. (Pubitemid 23277681)
19. Holmborn K, Ledin J, Smeds E, Eriksson I, Kusche-Gullberg M, Kjellen L. Heparan sulfate synthesized by mouse embryonic stem cells deficient in NDST1 and NDST2 is 6-O-sulfated but contains no N-sulfate groups. J Biol Chem. 2004;279:42355-42358. (Pubitemid 39372115)
20. Cheung WF, Eriksson I, Kusche-Gullberg M, Lindhal U, Kjellen L. Expression of the mouse mastocytoma glucosaminyl N-deacetylase/N- sulfotransferase in human kidney 293 cells results in increased N-sulfation of heparan sulfate. Biochemistry. 1996;35:5250-5256.
21. Ledin J, Staatz W, Li JP, Gotte M, Selleck S, Kjellen L, Spillmann D. Heparan sulfate structure in mice with genetically modified heparan sulfate production. J Biol Chem. 2004;279:42732-42741. (Pubitemid 39372160)
22. Kreuger J, Lindahl U, Jemth P. Nitrocellulose filter binding to assess binding of glycosaminoglycans to proteins. Methods Enzymol. 2003;363:327-339. (Pubitemid 37267681)
23. Jakobsson L, Kreuger J, Claesson-Welsh L. Building blood vessels-stem cell models in vascular biology. J Cell Biol. 2007;177:751-755. (Pubitemid 46873082)
24. Hirschi KK, Rohovsky SA, D'Amore PA. PDGF, TGF-beta, and heterotypic cell-cell interactions mediate endothelial cell-induced recruitment of 10T1/2 cells and their differentiation to a smooth muscle fate. J Cell Biol. 1998;141:805-814. (Pubitemid 28217923)
25. Hellstrom M, Kalen M, Lindahl P, Abramsson A, Betsholtz C. Role of PDGF-B and PDGFR-beta in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse. Development. 1999;126:3047-3055. (Pubitemid 29378170)
26. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signalling in control of vascular function. Nat Rev Mol Cell Biol. 2006;7:359-371.
27. Danielson KG, Baribault H, Holmes DF, Graham H, Kadler KE, Iozzo RV. Targeted disruption of decorin leads to abnormal collagen fibril morphology and skin fragility. J Cell Biol. 1997;136:729-743. (Pubitemid 27083772)
28. Nili N, Cheema AN, Giordano FJ, Barolet AW, Babaei S, Hickey R, Eskandarian MR, Smeets M, Butany J, Pasterkamp G, Strauss BH. Decorin inhibition of PDGF-stimulated vascular smooth muscle cell function: potential mechanism for inhibition of intimal hyperplasia after balloon angioplasty. Am J Pathol. 2003;163:869-878. (Pubitemid 37040123)
29. Schaefer L, Iozzo RV. Biological functions of the small leucine-rich proteoglycans: from genetics to signal transduction. J Biol Chem. 2008;283:21305-21309.
30. Goldoni S, Humphries A, Nystrom A, Sattar S, Owens RT, McQuillan DJ, Ireton K, Iozzo RV. Decorin is a novel antagonistic ligand of the Met receptor. J Cell Biol. 2009;185:743-754.
31. Seidler DG, Dreier R. Decorin and its galactosaminoglycan chain: extracellular regulator of cellular function? IUBMB Life. 2008;60:729-733.
32. Jarvelainen HT, Iruela-Arispe ML, Kinsella MG, Sandell LJ, Sage EH, Wight TN. Expression of decorin by sprouting bovine aortic endothelial cells exhibiting angiogenesis in vitro. Exp Cell Res. 1992;203:395-401. (Pubitemid 23035705)
33. Davies Cde L, Melder RJ, Munn LL, Mouta-Carreira C, Jain RK, Boucher Y. Decorin inhibits endothelial migration and tube-like structure formation: role of thrombospondin-1. Microvasc Res. 2001;62:26-42. (Pubitemid 32679304)
34. Grant DS, Yenisey C, Rose RW, Tootell M, Santra M, Iozzo RV. Decorin suppresses tumor cell-mediated angiogenesis. Oncogene. 2002;21:4765-4777. (Pubitemid 34879452)
35. Schonherr E, Sunderkotter C, Schaefer L, Thanos S, Grassel S, Oldberg A, Iozzo RV, Young MF, Kresse H. Decorin deficiency leads to impaired angiogenesis in injured mouse cornea. J Vasc Res. 2004;41:499-508. (Pubitemid 39656675)
36. Grako KA, Ochiya T, Barritt D, Nishiyama A, Stallcup WB. PDGF (alpha)-receptor is unresponsive to PDGF-AA in aortic smooth muscle cells from the NG2 knockout mouse. J Cell Sci. 1999;112(Pt 6):905-915. (Pubitemid 29179323)
37. Chekenya M, Hjelstuen M, Enger PO, Thorsen F, Jacob AL, Probst B, Haraldseth O, Pilkington G, Butt A, Levine JM, Bjerkvig R. NG2 proteoglycan promotes angiogenesis-dependent tumor growth in CNS by sequestering angiostatin. FASEB J. 2002;16:586-588.
38. Ozerdem U, Stallcup WB. Pathological angiogenesis is reduced by targeting pericytes via the NG2 proteoglycan. Angiogenesis. 2004;7:269-276.
39. Schlessinger J, Plotnikov AN, Ibrahimi OA, Eliseenkova AV, Yeh BK, Yayon A, Linhardt RJ, Mohammadi M. Crystal structure of a ternary FGF-FGFR-heparin complex reveals a dual role for heparin in FGFR binding and dimerization. Mol Cell. 2000;6:743-750.
40. Ibrahimi OA, Zhang F, Hrstka SC, Mohammadi M, Linhardt RJ. Kinetic model for FGF, FGFR, and proteoglycan signal transduction complex assembly. Biochemistry. 2004;43:4724-4730. (Pubitemid 38509093)
41. Andres JL, Ronnstrand L, Cheifetz S, Massague J. Purification of the transforming growth factor-beta (TGF-beta) binding proteoglycan betaglycan. J Biol Chem. 1991;266:23282-23287. (Pubitemid 21908791)
42. Cheifetz S, Andres JL, Massague J. The transforming growth factor-beta receptor type III is a membrane proteoglycan. Domain structure of the receptor. J Biol Chem. 1988;263:16984-16991. (Pubitemid 18268883)
43. Esparza-Lopez J, Montiel JL, Vilchis-Landeros MM, Okadome T, Miyazono K, Lopez-Casillas F. Ligand binding and functional properties of betaglycan, a co-receptor of the transforming growth factor-beta superfamily. Specialized binding regions for transforming growth factor-beta and inhibin A. J Biol Chem. 2001;276:14588-14596.
44. Eickelberg O, Centrella M, Reiss M, Kashgarian M, Wells RG. Betaglycan inhibits TGF-beta signaling by preventing type I-type II receptor complex formation. Glycosaminoglycan modifications alter betaglycan function. J Biol Chem. 2002;277:823-829. (Pubitemid 34952123)
45. Raza A, Franklin MJ, Dudek AZ. Pericytes and vessel maturation during tumor angiogenesis and metastasis. Am J Hematol. 2010;85:593-598.
46. Xian X, Hakansson J, Stahlberg A, Lindblom P, Betsholtz C, Gerhardt H, Semb H. Pericytes limit tumor cell metastasis. J Clin Invest. 2006;116:642-651. (Pubitemid 43326873)
47. Lindahl U. Heparan sulfate-protein interactions: a concept for drug design? Thromb Haemost. 2007;98:109-115. (Pubitemid 47074185)